科前生物
(688526)
| 流通市值：84.70亿 | | | 总市值：84.70亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 800,292,120.31 | 581,740,744.51 | 692,158,408.64 | 418,821,986.73 |
| 应收票据及应收账款 | 312,354,129.45 | 331,412,360.97 | 395,760,696.58 | 414,464,817.48 |
| 其中：应收票据 | - | - | - | 43,368,519.11 |
| 应收账款 | 312,354,129.45 | 331,412,360.97 | 395,760,696.58 | 371,096,298.37 |
| 应收款项融资 | 10 | 11,736,295.65 | - | - |
| 预付款项 | 3,690,384.25 | 7,690,320.37 | 6,994,347.2 | 10,000,239.53 |
| 其他应收款合计 | 3,892,107.21 | 3,728,772 | 3,414,101.1 | 4,178,062.83 |
| 存货 | 146,435,411.57 | 144,801,907.79 | 156,307,127.8 | 163,399,723.58 |
| 一年内到期的非流动资产 | 484,148,243.7 | 468,740,473.53 | 808,713,298.3 | 990,171,657.72 |
| 其他流动资产 | 26,846,425.51 | 271,195,549.53 | - | - |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,472,776,254.39 | 2,566,086,573.76 | 2,973,386,605.59 | 2,794,077,981.5 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 99,893,725.04 | 96,571,787.33 | 200,000 | 200,000 |
| 固定资产 | 775,940,117.7 | 799,006,067.68 | 822,059,486.28 | 839,292,722.62 |
| 在建工程 | 53,057,251.88 | 43,051,020.11 | 17,375,062.4 | 9,411,048.7 |
| 生产性生物资产 | 8,774,993.59 | 10,049,956.19 | 8,992,694.61 | - |
| 使用权资产 | 6,605,147.72 | 6,790,469.7 | 6,915,642.44 | 7,206,757.79 |
| 无形资产 | 58,521,528.16 | 60,028,728.9 | 58,873,976.16 | 58,025,415.66 |
| 商誉 | 3,307,452.36 | 3,307,452.36 | 3,307,452.36 | 3,307,452.36 |
| 长期待摊费用 | 1,107,993.33 | 1,178,483.34 | - | - |
| 递延所得税资产 | 505,197.92 | 299,894.73 | 34,862,399.37 | 31,869,607.77 |
| 其他非流动资产 | 1,137,894,416.58 | 1,084,879,036.91 | 811,770,335.63 | 788,125,728.89 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,145,607,824.28 | 2,105,162,897.25 | 1,764,357,049.25 | 1,737,438,733.79 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,618,384,078.67 | 4,671,249,471.01 | 4,737,743,654.84 | 4,531,516,715.29 |
| 流动负债: | | | | |
| 短期借款 | 155,080,327.87 | 206,650,359.95 | 228,155,489.48 | 238,151,191.8 |
| 应付票据及应付账款 | 120,825,592.32 | 165,029,720.01 | 180,035,723.14 | 188,579,923.2 |
| 其中：应付票据 | 17,062,000 | 32,693,495.9 | 40,242,163.9 | 22,006,168 |
| 应付账款 | 103,763,592.32 | 132,336,224.11 | 139,793,559.24 | 166,573,755.2 |
| 合同负债 | 203,846,267.32 | 157,606,070.48 | 207,216,391.12 | 137,019,169.65 |
| 应付职工薪酬 | 20,590,251.39 | 49,568,986.38 | 43,898,396.47 | 32,438,477.5 |
| 应交税费 | 63,175,411.27 | 57,815,317.67 | 46,713,522.34 | 28,483,561.32 |
| 其他应付款合计 | 40,301,728.7 | 39,636,442.51 | 55,622,260.18 | 48,840,284.55 |
| 一年内到期的非流动负债 | 31,175,720.11 | 81,113,415.88 | 81,075,698.41 | 51,042,298.8 |
| 其他流动负债 | 2,314,373.57 | 831,754.02 | 2,988,509.79 | 728,850.75 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 637,309,672.55 | 758,252,066.9 | 845,705,990.93 | 725,283,757.57 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 30,004,931.51 |
| 租赁负债 | 5,674,933.8 | 5,745,129.78 | 6,430,405.89 | 6,497,446.4 |
| 预计负债 | - | - | - | 1,989,553.8 |
| 递延收益 | 56,708,119.75 | 56,624,538.73 | 59,997,090.07 | 58,802,804.79 |
| 递延所得税负债 | 15,012,338.28 | 12,970,411.87 | 57,995,407.68 | 59,526,828.93 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 77,395,391.83 | 75,340,080.38 | 124,422,903.64 | 156,821,565.43 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 714,705,064.38 | 833,592,147.28 | 970,128,894.57 | 882,105,323 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 466,168,016 | 466,168,016 | 466,168,016 | 466,207,976 |
| 资本公积 | 1,140,618,473.05 | 1,140,618,473.05 | 1,134,625,423.4 | 1,135,129,718.6 |
| 减:库存股 | 24,950,912.37 | 574,624.8 | 574,624.8 | 1,118,880 |
| 其他综合收益 | 28,655,920.39 | 25,333,622.92 | - | - |
| 盈余公积 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 | 269,372,446.08 |
| 未分配利润 | 2,021,937,660.08 | 1,934,709,264.3 | 1,896,202,497.72 | 1,777,940,211.84 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,901,801,603.23 | 3,835,627,197.55 | 3,765,793,758.4 | 3,647,531,472.52 |
| 少数股东权益 | 1,877,411.06 | 2,030,126.18 | 1,821,001.87 | 1,879,919.77 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,903,679,014.29 | 3,837,657,323.73 | 3,767,614,760.27 | 3,649,411,392.29 |
| 负债和股东权益合计 | 4,618,384,078.67 | 4,671,249,471.01 | 4,737,743,654.84 | 4,531,516,715.29 |
| 公告日期 | 2024-04-30 | 2024-04-02 | 2023-10-27 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |